BioSpace News Archive

Business

Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook

Apyx Medical Corporation, a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, reported financial results for its third quarter ended September 30, 2019.

November 11, 2019
·
11 min read
Business

NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines

Clinical trial collaboration agreement leverages NEC’s cutting-edge AI technology and VAXIMM’s novel oral T-cell immunotherapy technology

November 11, 2019
·
3 min read
Drug Development

Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

First study to demonstrate a strong association between liver fat reduction by a pharmaceutical agent and improvement and resolution of NASH on liver biopsy

November 11, 2019
·
12 min read
Business

CORRECTING and REPLACING Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook

In the “2019 Financial Outlook” section, the fifth bulleted item should read: GAAP net loss in the range of $20.3 million to $19.8 million.

November 11, 2019
·
11 min read
Deals

Young Innovations Announces Acquisition of PuraGraft

Young Innovations, a leading global supplier of dental products, announced the acquisition of PuraGraft, LLC.

November 11, 2019
·
2 min read
Business

IRRAS Announces Addition of Dr. Coenraad Tamse as Vice President, International Sales

IRRAS, a global healthcare company with a comprehensive portfolio of innovative products for neurocritical care, announced the hiring of Dr. Coenraad Tamse as Vice President, International Sales.

November 11, 2019
·
3 min read
Policy

Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

Hutchison China MediTech Limited announces that its New Drug Application for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine tumors has been accepted for review by the China National Medical Products Administration.

November 11, 2019
·
9 min read
Pharm Country

Amarin to Present at the Jefferies 2019 London Healthcare Conference

Amarin Corporation plc announced that John F. Thero, Amarin’s president and chief executive officer, is scheduled to present a general company update at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 8:40 a.m. Greenwich Mean Time / 3:40 a.m. Eastern Time in London, UK.

November 11, 2019
·
2 min read
TTP plc Desktop Biology Enables Development and Manufacture of DnaNudge Technology

Novel multiplex technology developed to help consumers make healthier choices based on their genetic profile

November 11, 2019
·
3 min read
Business

Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Foamix Pharmaceuticals Ltd., a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced financial results for the three and nine months ended September 30, 2019 and provided a corporate update.

November 11, 2019
·
15 min read